Asnaashari Parasto, Kar Pran M, Borgan Saif, Karasik Olga
University of Central Florida, HCA Florida Healthcare, Orlando, Florida, USA.
Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.
Hemodial Int. 2025 Mar 4. doi: 10.1111/hdi.13211.
Urolithiasis is a common malady afflicting 8.8% of the general population. Its occurrence is also not uncommon in patients undergoing renal replacement therapy. Despite the leaping scientific advancement achieved in managing and preventing urolithiasis in the general population, there remains limited data regarding its prevention in patients undergoing renal replacement therapy.
We present a case of recurrent urolithiasis in a patient with end-stage renal disease on renal replacement therapy.
We performed a literature review on urolithiasis in patients with ESKD undergoing renal replacement therapy, emphasizing evidence-based available preventative strategies.
尿石症是一种常见疾病，影响着8.8%的普通人群。在接受肾脏替代治疗的患者中也并不罕见。尽管在普通人群中管理和预防尿石症方面取得了飞跃式的科学进步，但关于在接受肾脏替代治疗的患者中预防尿石症的数据仍然有限。
我们报告一例接受肾脏替代治疗的终末期肾病患者复发性尿石症的病例。
我们对接受肾脏替代治疗的终末期肾病患者的尿石症进行了文献综述，重点强调了基于证据的可用预防策略。
